https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-08-22 / Cancer Immunol. Immunother. 2018 Nov;67(11):1777-1788
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-08-22 / Cancer Immunol. Immunother. 2018 Nov;67(11):1777-17882018-08-22 00:00:002019-03-25 10:40:24Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-08-07 / Sci Rep 2018 Aug;8(1):11800
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-08-07 / Sci Rep 2018 Aug;8(1):118002018-08-07 00:00:002018-08-07 00:00:00Comparative effect of immunotherapy and standard therapy in patients with high grade glioma: a meta-analysis of published clinical trials
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-08-05 / BMJ Open 2018 08;8(8):e021701
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-08-05 / BMJ Open 2018 08;8(8):e0217012018-08-05 00:00:002018-08-05 00:00:00Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-07-30 / Oncoimmunology 2018;7(12):e1474318
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-07-30 / Oncoimmunology 2018;7(12):e14743182018-07-30 00:00:002018-07-30 00:00:00Low-dose cyclophosphamide depletes circulating naïve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-07-30 / Clin. Exp. Med. 2018 Nov;18(4):535-546
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-07-30 / Clin. Exp. Med. 2018 Nov;18(4):535-5462018-07-30 00:00:002018-07-30 00:00:00Immunotherapeutic strategies for treatment of hepatocellular carcinoma with antigen-loaded dendritic cells: in vivo study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-07-27 / Cancer Immunol. Immunother. 2018 Oct;67(10):1545-1558
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-07-27 / Cancer Immunol. Immunother. 2018 Oct;67(10):1545-15582018-07-27 00:00:002019-02-15 08:47:42High-grade glioma associated immunosuppression does not prevent immune responses induced by therapeutic vaccines in combination with T depletion
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-07-26 / Ther Clin Risk Manag 2018;14:1299-1313
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-07-26 / Ther Clin Risk Manag 2018;14:1299-13132018-07-26 00:00:002019-02-15 08:47:37Dendritic cell vaccines for high-grade gliomas
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-07-23 / Cancer Immunol. Immunother. 2018 Oct;67(10):1505-1518
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-07-23 / Cancer Immunol. Immunother. 2018 Oct;67(10):1505-15182018-07-23 00:00:002019-02-15 08:32:52A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-06-18 / Cancer Cell Int. 2018;18:85
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-06-18 / Cancer Cell Int. 2018;18:852018-06-18 00:00:002019-02-15 08:46:17Targeting dendritic cells in pancreatic ductal adenocarcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-06-04 / J Clin Oncol 36, 2018 (suppl; abstr 9525)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-06-04 / J Clin Oncol 36, 2018 (suppl; abstr 9525)2018-06-04 11:43:522019-07-17 11:44:13Interim analysis of a prospective, randomized, double blind, placebo controlled, phase IIb trial of the TLPLDC vaccine to prevent recurrence in resected stage III or IV melanoma patients.
